• Explore /
  • Poster
  • / Phase 3 study of first-line treatment with pembrolizumab + belzutifan + lenvatinib or pembrolizumab/quavonlimab + lenvatinib versus pembrolizumab + lenvatinib for advanced renal cell carcinoma (RCC).

Phase 3 study of first-line treatment with pembrolizumab + belzutifan + lenvatinib or pembrolizumab/quavonlimab + lenvatinib versus pembrolizumab + lenvatinib for advanced renal cell carcinoma (RCC).

Abstract Poster

Authors

Toni Choueiri

Toni K. Choueiri

Dana-Farber Cancer Institute and Harvard Medical School, Boston, MA

Toni K. Choueiri , Elizabeth R. Plimack , Thomas Powles , Martin H Voss , Howard Gurney , Rachel Kloss Silverman , Rodolfo F. Perini , Karla Rodriguez-Lopez , Brian I. Rini

Sign-In to See More Abstracts, Journal Articles, Posters, Videos and Slides and to Bookmark Your Favorite Content.

Disclaimer

This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org

Poster Details

Meeting

2022 ASCO Genitourinary Cancers Symposium

Session Type

Trials in Progress Poster Session

Session Title

Trials in Progress Poster Session C: Renal Cell Cancer; Adrenal, Penile, Urethral, and Testicular Cancers

Track

Renal Cell Cancer,Adrenal Cancer,Penile Cancer,Testicular Cancer,Urethral Cancer

Sub Track

Therapeutics

Clinical Trial Registration Number

NCT04736706

Citation

J Clin Oncol 40, 2022 (suppl 6; abstr TPS399)

DOI

10.1200/JCO.2022.40.6_suppl.TPS399

Abstract #

TPS399

Poster Bd #

M3

Abstract Disclosures

Similar Posters

First Author: Robert J. Motzer

First Author: Elizabeth R. Plimack

First Author: Christian Marth

First Author: Richard S. Finn